Clinical Trial Update: Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis [Phase 3]

View source ↗

Summary

Phase 3 trial investigating lanthanum carbonate (Fosrenol) to reduce oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria
• Nephrolithiasis

Drugs mentioned

• FOSRENOL (lanthanum carbonate)

Snippet

Sponsor: Universitair Ziekenhuis Brussel | Conditions: Secondary Hyperoxaluria, Nephrolithiasis | Phase 3 | Status: UNKNOWN